Controlling the troll: Management of cytomegalovirus infection after transplantation

被引：4

作者：

Dummer, S ^{[1
]}

机构：

[1] Vanderbilt Univ, Ctr Med, Nashville, TN 37232 USA

来源：

ANNALS OF INTERNAL MEDICINE | 2005年 / 143卷 / 12期

关键词：

D O I：

10.7326/0003-4819-143-12-200512200-00010

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Because of better antiviral drugs and sensitive viral assays, cytomegalovirus (CMV) disease is becoming less threatening to post-transplantation patients. However, proponents of universal antiviral drug prophylaxis cannot agree with those who prefer testing for CMV and treating as needed. In this issue, Kalil and colleagues present their meta-analysis of trials of these 2 approaches to CMV disease prevention. Because the study is a summary of previously published trials, it does not really break new ground. Nonetheless, it will probably affect thinking in this field. © 2005 American College of Physicians.

引用

收藏

页码：913 / 914

页数：2

相关论文

共 19 条

[1]

BALFOUR HH, 1980, CLIN MICROBIOLOGY NE, V2, P1

[2] Quantitation of cytomegalovirus: Methodologic aspects and clinical applications [J].

Boeckh, M ;

Boivin, G .

CLINICAL MICROBIOLOGY REVIEWS, 1998, 11 (03) :533-+

[3] Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation [J].

Cope, AV ;

Sabin, C ;

Burroughs, A ;

Rolles, K ;

Griffiths, PD ;

Emery, VC .

JOURNAL OF INFECTIOUS DISEASES, 1997, 176 (06) :1484-1490

[4] Infection in organ-transplant recipients [J].

Fishman, JA ;

Rubin, RH .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (24) :1741-1751

[5] A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients [J].

Humar, A ;

Kumar, D ;

Preiksaitis, J ;

Boivin, G ;

Siegal, D ;

Fenton, J ;

Jackson, K ;

Nia, S ;

Lien, D .

AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (06) :1462-1468

[6] Meta-analysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients [J].

Kalil, AC ;

Levitsky, J ;

Lyden, E ;

Stoner, J ;

Freifeld, AG .

ANNALS OF INTERNAL MEDICINE, 2005, 143 (12) :870-880

[7] Cytomegalovirus PP65 antigenemia monitoring as a guide for preemptive therapy: A cost effective strategy for prevention of cytomegalovirus disease in adult liver transplant recipients [J].

Kusne, S ;

Grossi, P ;

Irish, W ;

St George, K ;

Rinaldo, C ;

Rakela, J ;

Fung, J .

TRANSPLANTATION, 1999, 68 (08) :1125-1131

[8] RECOVERY OF HLA-RESTRICTED CYTOMEGALOVIRUS (CMV)-SPECIFIC T-CELL RESPONSES AFTER ALLOGENEIC BONE-MARROW TRANSPLANT - CORRELATION WITH CMV DISEASE AND EFFECT OF GANCICLOVIR PROPHYLAXIS [J].

LI, CR ;

GREENBERG, PD ;

GILBERT, MJ ;

GOODRICH, JM ;

RIDDELL, SR .

BLOOD, 1994, 83 (07) :1971-1979

[9] Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation [J].

Lowance, D ;

Neumayer, HH ;

Legendre, CM ;

Squifflet, JP ;

Kovarik, J ;

Brennan, PJ ;

Norman, D ;

Mendez, R ;

Keating, MR ;

Coggon, GL ;

Crisp, A ;

Lee, IC .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (19) :1462-1470

[10] The clinical impact of ganciclovir prophylaxis on the occurrence of bacteremia in orthotopic liver transplant recipients [J].

Munoz-Price, LS ;

Slifkin, M ;

Ruthazer, R ;

Poutsiaka, DD ;

Hadley, S ;

Freeman, R ;

Rohrer, R ;

Angelis, M ;

Cooper, J ;

Fairchild, R ;

Barefoot, L ;

Bloom, J ;

Fitzmaurice, S ;

Snydman, DR .

CLINICAL INFECTIOUS DISEASES, 2004, 39 (09) :1293-1299